Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cosmo Pharmaceuticals Ord Shs CMOPF

Healthcare
Cosmo Pharmaceuticals N.V. is a pharmaceutical company. The Company is focused on gastrointestinal (GI) diseases and dermatology. Its development pipeline is focused on Bowel Diseases, Colon Infections, and products to reduce the incidence of Colorectal Cancer (CRC) by increasing the detection of cancerous and pre-cancerous lesions during colonoscopy. Products which it has developed include... see more

Recent & Breaking News (PINL:CMOPF)

    Cosmo to Bring Real-Time AI into Intelligent Medical Devices with NVIDIA IGX

    Newsfile 11 days ago

    Cosmo Reports Excellent Final Full Year 2023 Financial Results - Increases Operating Profit Guidance for 2024 - Dividend of 2.00 per Share Will Be Proposed at EGM on 5 July 2024

    Newsfile May 31, 2024

    Cosmo Pharmaceuticals' Shareholders Approve All Agenda Items at Annual General Meeting

    Newsfile May 24, 2024

    Cosmo Has Received Approval of an Extension in Respect of the Publication and the Filing of Its Annual Report 2023

    Newsfile April 29, 2024

    Cosmo Announces Leadership Changes

    Newsfile April 25, 2024

    Cosmo and Medtronic Unveil the Future of AI in GI: Genius Summit 2024 Reveals Innovations and Collaborations That Advance Endoscopic Care

    Newsfile April 12, 2024

    Cosmo Reports Excellent Preliminary Unaudited Full Year 2023 Core Financial Results - Record Guidance for 2024 - Doubles Dividend to 2.00 per Share

    Newsfile March 20, 2024

    Cosmo Pharmaceuticals Announces Approval of Winlevi(R) in Australia

    Newsfile March 19, 2024

    Invitation to Cosmo's Investor Day and Full-Year 2023 Webcast - Zurich, 20 March 2024

    Newsfile January 25, 2024

    Cosmo Pharmaceuticals and Medtronic Forge Ahead in AI-Driven Care

    Newsfile December 11, 2023

    Invitation to Cosmo's GI Genius(TM) Q&A session for investors, analysts and journalist

    PR Newswire April 28, 2021

    Cosmo announces FDA approval of GI Genius(TM) intelligent endoscopy module, its revolutionary Artificial Intelligence device for lesion detection during colonoscopy

    PR Newswire April 12, 2021

    Cosmo Full-Year Report 2020: Cosmo returns to operating profit

    PR Newswire March 26, 2021

    Invitation to Cosmo's 2020 results / 2021 outlook presentation conference call on 26 March 2021

    PR Newswire March 19, 2021